New trial aims to shield hearts from chemo side effects
NCT ID NCT07572175
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called sotagliflozin can prevent heart, muscle, and fat damage caused by a common type of chemotherapy (anthracycline) in people with newly diagnosed lymphoma. About 60 adults who are scheduled to receive high-dose anthracycline will take either the drug or a placebo during treatment. The goal is to see if the drug helps keep the heart pumping strongly and reduces other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact